NuPathe (PATH +2.5%) says the U.S. Patent & Trademark Office has accepted its patent...

|By:, SA News Editor

NuPathe (PATH +2.5%) says the U.S. Patent & Trademark Office has accepted its patent application for iontophoretic patches, a migraine treatment containing the company's proprietary hydrogel polyamine formulation. The company expects the patent to be issued within the next few months, and should provide additional patent protection for its existing migraine treatment Zecuity.